Abstract

Introduction: Urinary tract infections (UTI) are one of the most frequent infectious processes worldwide. The estimated incidence of UTI in our country is currently unknown. The treatment will depend on the age, the sex, the isolated germ, among others. Fluoroquinolones have been considered as the ideal treatment in this infection. The most empirically used is ciprofloxacin; however, its resistance makes a marked decrease in the effectiveness of the treatment with this agent.
Objective: To describe the microbial resistance to ciprofloxacin in UTI as first-line treatment.
Methods: Descriptive, cross-sectional and retrospective study, through the review of clinical records of 217 patients, who had the diagnosis of UTI, with reported cultures, during the period January 2013 to December 2017.
Results: 82 patients were included (37.76%). The main germs that reported resistance were Escherichia coli (54.23%), Pseudomonas aeruginosa (11.86%). The most frequent comorbidity was Diabetes Mellitus. And the bacterial resistance reported in this study is 79.66%.
Discussion: Resistance to ciprofloxacin constitutes a serious public health problem due to its frequent use. E coli were the bacterium with the greatest resistance to this antibiotic, superior to the reviewed studies. The proportion of resistance exceeds that reported in other works.
Conclusion: Resistance to ciprofloxacin in urinary tract infection caused by common uropathogens is increasing. The use of this antibiotic agent as empirical therapy for UTI should be reconsidered and efforts should be made to limit its use to clinical conditions that warrant it.

Keywords

Ciprofloxacin, urinary tract infection, microbial resistance